跳到正文
原文
Endpoints News 生物医药· Ryan Cross·· 3 天前AI 评分21

Marrow 获 1.73 亿美元融资,推进 siRNA 药物治疗镰状细胞病以竞批 CRISPR 疗法

Marrow raises $173M for siRNA drug competing with CRISPR therapy for sickle cell

AI 导读

基因疗法公司 Marrow 宣布获得 1.73 亿美元融资,用于开发 siRNA 药物,该药物将在镰状细胞病领域与 CRISPR 疗法竞争。此前 FDA 于 2023 年 12 月批准了两种镰状细胞病基因疗法,引发多家药企关注这一赛道。

正文

When the FDA ap­proved two gene ther­a­pies for sick­le cell dis­ease in De­cem­ber 2023, many drug­mak­ers viewed it as the end of the sto­ry and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news